Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations

MustGrow: CEO Letter to Shareholders 2025

By The Northwire Desk — AI Analysis Dec 18, 2025 · 07:02 MGRO · 0.57 MustGrow Biologics Corp.
MGRO · Price

Executive Summary

  • MustGrow reports strong repeat demand for its mustard‑derived biofertility product TerraSante™ in the U.S., with field data indicating significant yield and revenue gains for farmers.
  • The company is scaling manufacturing capacity for 2026, expanding contract manufacturing in Asia, and pursuing additional production partners to meet growing demand.
  • Progress continues on biopesticide TerraMG™ registrations in Canada and the U.S., and on a commercial license agreement with Bayer AG for Europe, Middle East and Africa.

Key Details

  • TerraSante™ sales: Modest in H1 2025 (field‑trial purchases); accelerated in H2 2025 with repeat orders that exceeded inventory due to conservative planning.
  • Farmer feedback (Washington state): Reported ~2 t/acre increase in potato yields and ~35 % more high‑quality A/B potatoes; estimated US$5,000/acre value uplift at a product cost of US$180/acre.
  • Manufacturing scale‑up: Contract manufacturers in Asia are expanding dedicated production lines for continuous output in 2026, expected to improve margins versus current batch process.
  • International interest: Sales and distribution groups worldwide have expressed interest in registering and selling TerraSante™ as a biofertility/biostimulant product.
  • TerraMG™ registration progress: Additional field data from the 2025 BioAdvantage Trial (BAT) submitted to Canadian PMRA; two years of large‑scale Canadian field data now available, supporting upcoming registration.
  • Bayer Commercial License Agreement: Ongoing work with Bayer AG on TerraMG™ registration in EMEA; next milestone payment to MustGrow is anticipated soon.
  • NexusBioAg update: First full year of operation as MustGrow’s Canadian sales and distribution arm; serves as a ready‑made channel for TerraMG™ in Canada despite a cyclical 2025 market.
  • Outlook for 2026: Anticipated significant increase in TerraSante™ sales and margins, continued manufacturing expansion, and further progress on product registrations domestically and internationally.

Notable Quotes

“We experienced strong demand, farmer feedback has confirmed the economics and return‑on‑investment proposition and market size is significant and validated… We look forward to a significant increase in sales and margins on our signature mustard‑derived biofertility product.” – Corey Giasson, President & CEO

The release also confirms TSX Venture Exchange approval of previously announced August 2025 transactions (LIFE Offering, warrant repricing, and share‑for‑debenture settlement), with no changes to those terms.

Read the original news release →

More from MustGrow Biologics Corp.

Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings Jun 17, 2026 · 19:22

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other